AG
CERE

Algert Global’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Algert Global’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,742
Closed -$1.63M – 1667
2024
Q2 		$1.63M Buy
39,742
+7,312
+23% +$305K 0.05% 530
2024
Q1 		$1.37M Buy
32,430
+1,160
+4% +$48.7K 0.05% 532
2023
Q4 		$1.33M Buy
+31,270
New +$899K 0.05% 540

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Algert Global's CERE Position: Q3 2024 in Review

Algert Global sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 39,742 shares — an estimated $1.63M sold.

Algert Global first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $1.63M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Algert Global reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Algert Global sold 39,742 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.63M.
  • Algert Global first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Algert Global's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.63M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Algert Global's 13F filing for Q3 2024, filed 12 Nov 2024.